QuantiFERON–CMV is not available in the United States.
QuantiFERON–CMV is CE marked for commercial use in Europe


Search Results: Displaying all items (7)

First Author Title Journal Publication Date
Picat MQ. Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients. PloS one 2017
Forner G. CMV-ELISPOT but not CMV-QuantiFERON assay is a novel biomarker to determine the risk of congenital CMV infection in pregnant women. Journal of clinical microbiology 2016
Eldar-Yedidia Y. Low Interferon Relative-Response to Cytomegalovirus Is Associated with Low Likelihood of Intrauterine Transmission of the Virus. PloS one 2016
Castón JJ. Interferon-γ production by CMV-specific CD8+ T lymphocytes provides protection against cytomegalovirus reactivation in critically ill patients. Intensive care medicine 2016
Saldan A. Comparison of cell-mediated immune assays CMV-ELISPOT and CMV-QuantiFERON in CMV seropositive and seronegative pregnant and non-pregnant women. Journal of clinical microbiology 2016
Singh KP. Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery. Clinical immunology (Orlando, Fla.) 2007
Russell AS. QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy. Clinical rheumatology 2013